Literature DB >> 23779108

The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Rahman M Mizanur1, Verna Frasca, Subramanyam Swaminathan, Sina Bavari, Robert Webb, Leonard A Smith, S Ashraf Ahmed.   

Abstract

Botulinum neurotoxins are the most toxic of all compounds. The toxicity is related to a poor zinc endopeptidase activity located in a 50-kDa domain known as light chain (Lc) of the toxin. The C-terminal tail of Lc is not visible in any of the currently available x-ray structures, and it has no known function but undergoes autocatalytic truncations during purification and storage. By synthesizing C-terminal peptides of various lengths, in this study, we have shown that these peptides competitively inhibit the normal catalytic activity of Lc of serotype A (LcA) and have defined the length of the mature LcA to consist of the first 444 residues. Two catalytically inactive mutants also inhibited LcA activity. Our results suggested that the C terminus of LcA might interact at or near its own active site. By using synthetic C-terminal peptides from LcB, LcC1, LcD, LcE, and LcF and their respective substrate peptides, we have shown that the inhibition of activity is specific only for LcA. Although a potent inhibitor with a Ki of 4.5 μm, the largest of our LcA C-terminal peptides stimulated LcA activity when added at near-stoichiometric concentration to three versions of LcA differing in their C-terminal lengths. The result suggested a product removal role of the LcA C terminus. This suggestion is supported by a weak but specific interaction determined by isothermal titration calorimetry between an LcA C-terminal peptide and N-terminal product from a peptide substrate of LcA. Our results also underscore the importance of using a mature LcA as an inhibitor screening target.

Entities:  

Keywords:  Botulinum Toxin; C Terminus; Enzyme Mechanisms; Enzyme Structure; Metalloprotease; Neurotoxin; Peptide Interactions; Protein Chemistry; Zinc Endopeptidase

Mesh:

Substances:

Year:  2013        PMID: 23779108      PMCID: PMC3745367          DOI: 10.1074/jbc.M113.451286

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding.

Authors:  Tim Bartels; Logan S Ahlstrom; Avigdor Leftin; Frits Kamp; Christian Haass; Michael F Brown; Klaus Beyer
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Factors affecting autocatalysis of botulinum A neurotoxin light chain.

Authors:  S Ashraf Ahmed; Matthew L Ludivico; Leonard A Smith
Journal:  Protein J       Date:  2004-10       Impact factor: 2.371

3.  Extreme sensitivity of botulinum neurotoxin domains towards mild agitation.

Authors:  Stephen I Toth; Leonard A Smith; S Ashraf Ahmed
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

4.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

5.  Expression, purification, and characterization of Clostridium botulinum type B light chain.

Authors:  Janice Gilsdorf; Nizamettin Gul; Leonard A Smith
Journal:  Protein Expr Purif       Date:  2005-10-26       Impact factor: 1.650

6.  Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.

Authors:  Martha Hale; George Oyler; Subramanyam Swaminathan; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

7.  An intrinsically disordered C terminus allows the La protein to assist the biogenesis of diverse noncoding RNA precursors.

Authors:  Nathan J Kucera; Michael E Hodsdon; Sandra L Wolin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-06       Impact factor: 11.205

8.  Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex.

Authors:  Nicholas R Silvaggi; David Wilson; Saul Tzipori; Karen N Allen
Journal:  Biochemistry       Date:  2008-05-06       Impact factor: 3.162

9.  Unique substrate recognition by botulinum neurotoxins serotypes A and E.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2006-02-14       Impact factor: 5.157

10.  Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.

Authors:  Nicholas R Silvaggi; Grant E Boldt; Mark S Hixon; Jack P Kennedy; Saul Tzipori; Kim D Janda; Karen N Allen
Journal:  Chem Biol       Date:  2007-05
View more
  7 in total

1.  Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Authors:  Alan R Jacobson; Michael Adler; Nicholas R Silvaggi; Karen N Allen; Genessa M Smith; Ross A Fredenburg; Ross L Stein; Jong-Beak Park; Xiaochuan Feng; Charles B Shoemaker; Sharad S Deshpande; Michael C Goodnough; Carl J Malizio; Eric A Johnson; Sabine Pellett; William H Tepp; Saul Tzipori
Journal:  Toxicon       Date:  2017-07-08       Impact factor: 3.033

2.  The impacts of cytoplasmic incompatibility factor (cifA and cifB) genetic variation on phenotypes.

Authors:  J Dylan Shropshire; Rachel Rosenberg; Seth R Bordenstein
Journal:  Genetics       Date:  2021-03-03       Impact factor: 4.562

3.  Cleavage of SNAP25 and its shorter versions by the protease domain of serotype A botulinum neurotoxin.

Authors:  Rahman M Mizanur; Robert G Stafford; S Ashraf Ahmed
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

4.  Bioinformatic discovery of a toxin family in Chryseobacterium piperi with sequence similarity to botulinum neurotoxins.

Authors:  Michael James Mansfield; Travis Gwynn Wentz; Sicai Zhang; Elliot Jeon Lee; Min Dong; Shashi Kant Sharma; Andrew Charles Doxey
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

5.  Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies.

Authors:  Kwok-Ho Lam; Jacqueline M Tremblay; Kay Perry; Konstantin Ichtchenko; Charles B Shoemaker; Rongsheng Jin
Journal:  PLoS Pathog       Date:  2022-01-06       Impact factor: 6.823

6.  Reengineering the specificity of the highly selective Clostridium botulinum protease via directed evolution.

Authors:  Rebekah P Dyer; Hariny M Isoda; Gabriela S Salcedo; Gaetano Speciale; Madison H Fletcher; Linh Q Le; Yi Liu; Karen Brami-Cherrier; Shiazah Z Malik; Edwin J Vazquez-Cintron; Andrew C Chu; David C Rupp; Birgitte P S Jacky; Thu T M Nguyen; Benjamin B Katz; Lance E Steward; Sudipta Majumdar; Amy D Brideau-Andersen; Gregory A Weiss
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

7.  A novel role of C-terminus in introducing a functionally flexible structure critical for the biological activity of botulinum neurotoxin.

Authors:  Thomas M Feltrup; Kruti Patel; Raj Kumar; Shuowei Cai; Bal Ram Singh
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.